Stock & Company Details
Delcath Systems Inc $DCTH
Price:
N/A
N/A
35M
$669M
52 Week High:
N/A
10 Day Average Volume:
N/A
124.21
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
DCTH technical indicators
Latest Delcath Systems Inc (DCTH) indicator readings as of 2026-11-19.
DCTH's 14-day RSI is 60.9, in neutral territory. ADX reads 35.0, indicating a trending market. MACD (12, 26, 9) is 1.32, above the zero line.
Overview
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. Our investigational product, HEPZATO KIT™ (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. HEPZATO KIT has not been approved by the U.S. Food & Drug Administration (FDA) for sale in the U.S. In Europe, our system is marketed under the trade name Delcath CHEMOSAT® Hepatic Delivery System for Melphalan (CHEMOSAT) and has been CE Marked and used at major medical centers to treat a wide range of cancers of the liver. CHEMOSAT is being marketed under an exclusive licensing agreement with medac GmbH, a privately held multi-national pharmaceutical company headquartered in Germany that specializes in the treatment and diagnosis of oncological, urological and autoimmune diseases.
Finance Bot
Ask your questions
Start by typing a question below.